BioNTech, OncoC4 Report Positive Overall Survival Data From Phase 3 Trial of Gotistobart in Lung Cancer

MT Newswires Live09-14 17:04

BioNTech (BNTX) and OncoC4 said Monday that updated data from the first stage of their phase 3 PRESERVE-003 trial showed a statistically significant overall survival benefit for gotistobart in patients previously treated with squamous non-small cell lung cancer.

The company said data showed that gotistobart nearly doubled overall survival compared with standard-of-care chemotherapy in 87 patients in the trial.

Median overall survival was 18.5 months for patients treated with gotistobart compared with 10 months for those receiving standard-of-care docetaxel chemotherapy, according to the statement.

Gotistobart's safety profile "remained manageable" and consistent with previously reported data, the partners added. The companies said about 44 out of every 100 patients taking gotistobart experienced a serious side effect related to the treatment, compared with about 49 out of every 100 patients taking docetaxel.

BioNTech shares were up 2.9% in Monday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2667651466?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667651466","market":"sh","top_or_hot":-1,"title":"BioNTech, OncoC4 Report Positive Overall Survival Data From Phase 3 Trial of Gotistobart in Lung Cancer","media":"MT Newswires Live","content":"<html><body><p> BioNTech (BNTX) and OncoC4 said Monday that updated data from the first stage of their phase 3 PRESERVE-003 trial showed a statistically significant overall survival benefit for gotistobart in patients previously treated with squamous non-small cell lung cancer.</p><p>The company said data showed that gotistobart nearly doubled overall survival compared with standard-of-care chemotherapy in 87 patients in the trial.</p><p>Median overall survival was 18.5 months for patients treated with gotistobart compared with 10 months for those receiving standard-of-care docetaxel chemotherapy, according to the statement.</p><p>Gotistobart's safety profile \"remained manageable\" and consistent with previously reported data, the partners added. The companies said about 44 out of every 100 patients taking gotistobart experienced a serious side effect related to the treatment, compared with about 49 out of every 100 patients taking docetaxel.</p><p>BioNTech shares were up 2.9% in Monday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, OncoC4 Report Positive Overall Survival Data From Phase 3 Trial of Gotistobart in Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, OncoC4 Report Positive Overall Survival Data From Phase 3 Trial of Gotistobart in Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-14 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BioNTech (BNTX) and OncoC4 said Monday that updated data from the first stage of their phase 3 PRESERVE-003 trial showed a statistically significant overall survival benefit for gotistobart in patients previously treated with squamous non-small cell lung cancer.</p><p>The company said data showed that gotistobart nearly doubled overall survival compared with standard-of-care chemotherapy in 87 patients in the trial.</p><p>Median overall survival was 18.5 months for patients treated with gotistobart compared with 10 months for those receiving standard-of-care docetaxel chemotherapy, according to the statement.</p><p>Gotistobart's safety profile \"remained manageable\" and consistent with previously reported data, the partners added. The companies said about 44 out of every 100 patients taking gotistobart experienced a serious side effect related to the treatment, compared with about 49 out of every 100 patients taking docetaxel.</p><p>BioNTech shares were up 2.9% in Monday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2667651466","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667651466","pubTimestamp":1789376674,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BioNTech (BNTX) and OncoC4 said Monday that updated data from the first stage of their phase 3 PRESERVE-003 trial showed a statistically significant overall survival benefit for gotistobart in patient","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4551":"寇图资本持仓","BNTX":"BioNTech SE","BK4588":"碎股","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓"},"translate_title":"BioNTech 和 OncoC4 报告 Gotistobart 治疗肺癌 3 期试验的积极总生存率数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1},"content_text":"BioNTech (BNTX) and OncoC4 said Monday that updated data from the first stage of their phase 3 PRESERVE-003 trial showed a statistically significant overall survival benefit for gotistobart in patients previously treated with squamous non-small cell lung cancer.The company said data showed that gotistobart nearly doubled overall survival compared with standard-of-care chemotherapy in 87 patients in the trial.Median overall survival was 18.5 months for patients treated with gotistobart compared with 10 months for those receiving standard-of-care docetaxel chemotherapy, according to the statement.Gotistobart's safety profile \"remained manageable\" and consistent with previously reported data, the partners added. The companies said about 44 out of every 100 patients taking gotistobart experienced a serious side effect related to the treatment, compared with about 49 out of every 100 patients taking docetaxel.BioNTech shares were up 2.9% in Monday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2667651466","isCrawlerRequest":true}